UBS Hires Financial Advisor Shahan Avakian in Walnut Creek
UBS to Integrate Insightsoftware Into US Workplace Wealth Solutions Business
UBS Advisor Adam Epstein Named a Forbes Top Wealth Advisor
UBS Unveils New Workplace Wealth Solutions Technology for Global Stock Plan Issuers
UBS Group: Lowered PHARMARON's Target Price to HKD 20.8, rating "Buy".
UBS Group released a research report stating that PHARMARON (03759) had a revenue increase of 16% year-on-year in the first quarter to 3.1 billion RMB, exceeding market expectations, while net profit rose by 32.5% year-on-year to 0.306 billion RMB, falling short of market expectations. The company maintains its revenue target for this year, which is a year-on-year growth of 10% to 15%. The bank stated that based on this year's first-quarter performance, it believes the company's fundamentals are improving, although the extent of improvement is more moderate than expected. The bank has lowered its profit margin forecasts for this and next year, reducing the earnings per share estimates to 1.04 RMB and 1.27 RMB respectively, but it still maintains its long-term recovery outlook for the company, based on cash flow.
UBS Group: Expects SAMSONITE's secondary listing in the USA to be delayed, downgrading the rating to 'neutral'.
UBS Group released a Research Report stating that due to USA tariffs being heavier and broader than expected, SAMSONITE (01910) rating was downgraded from "Buy" to "Neutral," with the Target Price cut from 28.7 HKD to 15 HKD. The bank expects the North American market to face significant demand and gross profit impacts, and while maintaining a positive view on the company's long-term growth potential, it anticipates challenges for the company's near-term earnings. The bank mentioned that current market fluctuations may delay the company's timetable for a second listing in the USA. It stated that the company's current valuation is reasonable, with limited space for a rating downgrade, and the Global recession may reflect further downward pressure on earnings.
73903871 : UBS Group's stock price has plunged; are there any issues with its fundamentals?
RenenoMirai OP 73903871 : Dont think so, Wait until P/B under 1 then topup